Premium
Phannacokinetics of Intravenous Immunoglobulin in Neonates
Author(s) -
Weisman Leonard E.,
Fischer Gerald W,
Marinelli Philip,
Hemming Val G.,
Pierce John R.,
Golden Stephen M.,
Peck Carl C.
Publication year - 1989
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.1989.tb00836.x
Subject(s) - pharmacokinetics , antibiotics , medicine , antibody , dosing , sepsis , neonatal sepsis , streptococcus , toxicity , pharmacology , immunology , gastroenterology , biology , microbiology and biotechnology , bacteria , genetics
. Intravenous immunoglobulin (IVIG) may be a therapeutic adjunct to antibiotic treatment of neonatal infections. We examined the pharmacokinetics and safety of IVIG in human neonates. Thirty neonates with suspected sepsis were randomly assigned either to a treatment (receiving either 250, 500, or 1,000 mg/kg of IVIG plus antibiotics) or control (antibiotics alone) group. The 500 mg/kg dose produced a rise in total IgG for >8 and in group B streptococcus (GBS) type‐specific IgG for > 4–14 days. The type‐specific antibody elevation varied with the amount of pathogen‐specific antibody and dose of IVIG. Pharmacokinetic analysis suggests a Vd ss of 42ml/kg, Cl of 3.0ml/kg/day, a biphasic elimination curve, and a terminal elimination half‐life of 24.2 days. No toxicity was observed. These data may be valuable in determining optimal dosing schedules for IVIG in treating or preventing neonatal infections.